References
- Kasichayanula, S.; Liu, X.; LaCreta, F.; Griffen, S. C.; Boulton, D. W. Clinical Pharmacokinetics and Pharmacodynamics of Dapagliflozin, a Selective Inhibitor of Sodium-Glucose co-Transporter Type 2. Clin. Pharmacokinet. 2014, 53, 17–27. DOI: https://doi.org/10.1007/s40262-013-0104-3.
- American Diabetes Association. Standards of Medical Care in Diabetes - 2020. Diabetes Care 2020, 43, S1–S211. https://care.diabetesjournals.org/content/diacare/suppl/2019/12/20/43.Supplement_1.DC1/DC_43_S1_2020.pdf.
- Marsenic, O. Glucose Control by the Kidney: An Emerging Target in Diabetes. Am. J. Kidney Dis. 2009, 53, 875–883. https://www.sciencedirect.com/science/article/pii/S0272638609001486. DOI: https://doi.org/10.1053/j.ajkd.2008.12.031.
- Anderson, S. L. Dapagliflozin Efficacy and Safety: A Perspective Review. Ther. Adv. Drug Saf. 2014, 5, 242–254. https://doi.org/10.1177%2F2042098614551938. DOI: https://doi.org/10.1177/2042098614551938.
- Danaei, G.; Finucane, M. M.; Lu, Y.; Singh, G. M.; Cowan, M. J.; Paciorek, C. J.; Lin, J. K.; Farzadfar, F.; Khang, Y.-H.; Stevens, G. A.; Rao, M.; Ali, M. K. National, Regional, and Global Trends in Fasting Plasma Glucose and Diabetes Prevalence since 1980: systematic Analysis of Health Examination Surveys and Epidemiological Studies with 370 Country-Years and 2·7 Million Participants. Lancet 2011, 378, 31–40. https://www.sciencedirect.com/science/article/pii/S014067361160679x. DOI: https://doi.org/10.1016/S0140-6736(11)60679-X.
- American Diabetes Association. Standards of Medical Care in Diabetes - 2014. Diabetes Care 2014, 1, 176–178. https://www.ncbi.nlm.nih.gov/pubmed/24357209.
- Casagrande, S. S.; Fradkin, J. E.; Saydah, S. H.; Rust, K. F.; Cowie, C. C. The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals among People with Diabetes, 1988–2010. Diabetes Care 2013, 36, 2271–2279. DOI: https://doi.org/10.2337/dc12-2258.
- Fowler, M. J. Pitfalls in Outpatient Diabetes Management and Inpatient Glycemic Control. Clin. Diabetes 2011, 29, 79–85. DOI: https://doi.org/10.2337/diaclin.29.2.79.
- Buse, J. B.; Wexler, D. J.; Tsapas, A.; Rossing, P.; Mingrone, G.; Mathieu, C.; D'Alessio, D. A.; Davies, M. J. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020, 43, 487–493. DOI: https://doi.org/10.2337/dci19-0066.
- Ramachandran, A.; Das, A. K.; Joshi, S. R.; Yajnik, C. S.; Shah, S.; Kumar, K. P. Current Status of Diabetes in India and Need for Novel Therapeutic Agents. J. Assoc. Physicians India 2010, 58, 7–9. http://www.japi.org/june_special_issue_2010/Article_02.pdf.
- Komoroski, B.; Vachharajani, N.; Feng, Y.; Li, L.; Kornhauser, D.; Pfister, M. Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control over 2 Weeks in Patients with Type 2 Diabetes Mellitus. Clin. Pharmacol. Ther. 2009, 85, 513–519. DOI: https://doi.org/10.1038/clpt.2008.250.
- Chao, E. C.; Henry, R. R. SGLT2 Inhibition-a Novel Strategy for Diabetes Treatment. Nat. Rev. Drug Discov. 2010, 9, 551–559. DOI: https://doi.org/10.1038/nrd3180.
- Vallon, V. The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus. Annu. Rev. Med. 2015, 66, 255–270. DOI: https://doi.org/10.1146/annurev-med-051013-110046.
- Plosker, G. L. Dapagliflozin: A Review of Its Use in Patients with Type 2 Diabetes. Drugs 2014, 74, 2191–2209. DOI: https://doi.org/10.1007/s40265-014-0324-3.
- Ponnusamy, S.; Zinjarde, S.; Bhargava, S.; Kulkarni-Kale, U.; Sawant, S.; Ravikumar, D. The Inactivation of Human Pancreatic α-Amylase, an Antidiabetic Target, by Bisdemethoxycurcumin, a Small Molecule Inhibitor, Isolated from Curcuma Longa. Nat. Prod. J. 2013, 3, 15–25. https://www.ingentaconnect.com/content/ben/npj/2013/00000003/00000001/art00005. DOI: https://doi.org/10.2174/2210315511303010005.
- Shubrook, J. H.; Bokaie, B. B.; Adkins, S. E. Empagliflozin in the Treatment of Type 2 Diabetes: evidence to Date. Drug Des. Dev. Ther. 2015, 9, 5793–5803. DOI: https://doi.org/10.2147/DDDT.S69926.
- Usman, M. S.; Siddiqi, T. J.; Memon, M. M.; Khan, M. S.; Rawasia, W. F.; Talha Ayub, M.; Sreenivasan, J.; Golzar, Y. Sodium-Glucose co-Transporter 2 Inhibitors and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. Eur. J. Prev. Cardiolog. 2018, 25, 495–502. https://doi.org/10.1177%2F2047487318755531. DOI: https://doi.org/10.1177/2047487318755531.
- Ehrenkranz, J. R.; Lewis, N. G.; Ronald Kahn, C.; Roth, J. Phlorizin: A Review. Diabetes. Metab. Res. Rev. 2005, 21, 31–38. DOI: https://doi.org/10.1002/dmrr.532.
- Giugliano, D.; Maiorino, M. I.; Longo, M.; Esposito, K. Are Gliflozins the New Statins for Diabetes? Diabetes Res. Clin. Pract. 2019, 153, 191–193. DOI: https://doi.org/10.1016/j.diabres.2019.04.014.
- Abdul-Ghani, M. A.; DeFronzo, R. A.; Norton, L. Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30–50% of Filtered Glucose Load in Humans. Diabetes 2013, 62, 3324–3328. DOI: https://doi.org/10.2337/db13-0604.
- Faillie, J. L. Pharmacological Aspects of the Safety of Gliflozins. Pharmacol. Res. 2017, 118, 71–81. DOI: https://doi.org/10.1016/j.phrs.2016.07.001.
- Polidori, D.; Sha, S.; Ghosh, A.; Plum-Mörschel, L.; Heise, T.; Rothenberg, P. Validation of a Novel Method for Determining the Renal Threshold for Glucose Excretion in Untreated and Canagliflozin-Treated Subjects with Type 2 Diabetes Mellitus. J. Clin. Endocrinol. Metab. 2013, 98, E867–871. DOI: . DOI: https://doi.org/10.1210/jc.2012-4205.
- Obermeier, M.; Yao, M.; Khanna, A.; Koplowitz, B.; Zhu, M.; Li, W.; Komoroski, B.; Kasichayanula, S.; Discenza, L.; Washburn, W.; Meng, W.; et al. In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans. Drug Metab. Dispos. 2010, 38, 405–414. DOI: https://doi.org/10.1124/dmd.109.029165.
- Davis, C. S.; Fleming, J. W.; Warrington, L. E. Sodium Glucose co-Transporter 2 Inhibitors: A Novel Approach to the Management of Type 2 Diabetes Mellitus. J. Am. Assoc. Nurse Pract. 2014, 26, 356–363. DOI: https://doi.org/10.1002/2327-6924.12135.
- Sha, S.; Polidori, D.; Farrell, K.; Ghosh, A.; Natarajan, J.; Vaccaro, N.; Pinheiro, J.; Rothenberg, P.; Plum‐Mörschel, L. Pharmacodynamic Differences between Canagliflozin and Dapagliflozin: Results of a Randomized, Double‐Blind, Crossover Study. Diabetes. Obes. Metab. 2015, 17, 188–197. DOI: https://doi.org/10.1111/dom.12418.
- Yang, L.; Li, H.; Li, H.; Bui, A.; Chang, M.; Liu, X.; Kasichayanula, S.; Griffen, S. C.; LaCreta, F. P.; Boulton, D. W. Pharmacokinetic and Pharmacodynamic Properties of Single-and Multiple-Dose of Dapagliflozin, a Selective Inhibitor of SGLT2, in Healthy Chinese Subjects. Clin. Ther. 2013, 35, 1211–1222. DOI: https://doi.org/10.1016/j.clinthera.2013.06.017.
- Levine, J. A.; Lo, A. A.; Wallia, A.; Rogers, M.; VanWagner, L. B. Dapagliflozin-Induced Acute-on-Chronic Liver Injury. ACG Case Rep. J. 2016, 3, 1–4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5171930/.
- Thomas, M. C. Renal Effects of Dapagliflozin in Patients with Type 2 Diabetes. Ther. Adv. Endocrinol. Metab. 2014, 5, 53–61. https://doi.org/10.1177%2F2042018814544153. DOI: https://doi.org/10.1177/2042018814544153.
- FDA Drug Approval Package: Dapagliflozin. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000TOC.cfm (Accessed Jan 30, 2020).
- Australian Public Assessment Report for Dapagliflozin propanediol monohydrate. January 2013. https://www.tga.gov.au/sites/default/files/auspar-dapagliflozin-propanediol-monohydrate-130114.pdf (accessed Jun 11, 2019).
- Product Information, Dapagliflozin. https://www.caymanchem.com/pdfs/11574.pdf (accessed Jun 11, 2019).
- https://www.medplusmart.com/compositionProducts/Dapagliflozin-10-MG/29059 (accessed Jan 21, 2020).
- https://www.drugs.com/ingredient/dapagliflozin.html (accessed Jan 21, 2020).
- Gundala, A.; Prasad, K. V.; Koganti, B. Application of Quality by Design Approach in RP-HPLC Method Development for Simultaneous Estimation of Saxagliptin and Dapagliflozin in Tablet Dosage Form. Braz. J. Pharm. Sci. 2019, 55, 1–10. https://doi.org/10.1590/s2175-97902019000218129.
- Ameeduzzafa, El-Bagory, I.; Alruwaili, N. K.; Imam, S. S.; Alomar, F. A.; Elkomy, M. H.; Ahmad, N.; Elmowafy, M. Quality by Design (QbD) Based Development and Validation of Bioanalytical RP-HPLC Method for Dapagliflozin: Forced Degradation and Preclinical Pharmacokinetic Study. J. Liq. Chromatogr. Relat. Technol. 2020, 43, 53–65. DOI: https://doi.org/10.1080/10826076.2019.1667820.
- Mabrouk, M. M.; Soliman, S. M.; El-Agizy, H. M.; Mansou, F. R. Ultrasound-Assisted Dispersive Liquid–Liquid Microextraction for Determination of Three Gliflozins in Human Plasma by HPLC/DAD. J. Chromatogr. B 2019, 1136, 1–32. https://doi.org/10.1016/j.jchromb.2019.121932.
- Kant, R.; Bodla, R. B.; Kapoor, G.; Bhutani, R. Optimization of a Single HPLC-PDA Method for Quantifying Metformin, Gliclazide, Pioglitazone, Dapagliflozin, Empagliflozin, Saxagliptin, Linagliptin and Teneligliptin Using Central Composite Design. Bioorg. Chem. 2019, 91, 103–111. https://doi.org/10.1016/j.bioorg.2019.103111.
- Zaghary, W. A.; Mowaka, S.; Hendy, M. S. Kinetic Degradation Study of Dapagliflozin Coupled with UHPLC Separation in the Presence of Major Degradation Product and Metformin. Chromatographia 2019, 82, 777–789. DOI: https://doi.org/10.1007/s10337-019-03702-3.
- Vaghela, Y. V.; Patani, P.; Patel, D. Development and Validation of Stability Indicating Estimation Method of Dapagliflozin in It’stablet Dosage Form. Int. J. Res. Anal. Rev. 2019, 6, 206–213. https://ijrar.com/upload_issue/ijrar_issue_20543502.pdf.
- Donepudi, S.; Achanta, S. Simultaneous Estimation of Saxagliptin and Dapagliflozin in Human Plasma by Validated High Performance Liquid Chromatography-Ultraviolet Method. Turkish J. Pharm. Sci. 2019, 16, 227–233. DOI: https://doi.org/10.4274/tjps.galenos.2018.46547.
- Rao, B. R.; Rao, V. V.; Venkateswarlu, B. S. RP-HPLC Method for Simultaneous Estimation of Dapagliflozin and Saxagliptin in Bulk Samples. J. Pharm. Sci. Res. 2019, 11, 254–257. http://search.proquest.com/openview/a35213428a3c3fba6c53f5f58291104f/1?pq-origsite=gscholar&cbl=54977.
- Deepan, T.; Dhanaraju, M. D. Stability Indicating HPLC Method for the Simultaneous Determination of Dapagliflozin and Saxagliptin in Bulk and Tablet Dosage Form. Curr. Issues Pharm. Med. Sci. 2018, 31, 39–43. https://www.degruyter.com/downloadpdf/j/cipms.2018.31.issue-1/cipms-2018-0009/cipms-2018-0009.pdf. DOI: https://doi.org/10.1515/cipms-2018-0009.
- Singh, N.; Bansal, P.; Maithani, M.; Chauhan, Y. Development and Validation of a Stability-Indicating RP-HPLC Method for Simultaneous Determination of Dapagliflozin and Saxagliptin in Fixed-Dose Combination. New J. Chem. 2018, 42, 2459–2466. DOI: https://doi.org/10.1039/C7NJ04260D.
- Aswini, R.; Eswarudu, M. M.; Babu, p. A Novel RP-HPLC Method for Simultaneous Estimation of Dapagliflozin and Saxagliptin in Bulk and Pharmaceutical Dosage Form. Int. J. Pharm. Sci. Res. 2018, 9, 5161–5167.
- Padmaja, B. R.; Sivagami, B.; Chandrasekar, R. A Highly Validated RP-HPLC Method Development for the Simultaneous Estimation of Dapagliflozin and Saxagliptin in Tablet Dosage Forms. Int. J. Pharm. Sci. Drug Res. 2018, 10, 372–378. https://pdfs.semanticscholar.org/5e59/989a0211e3fc646e5c6346edeeea7b0a2eb7.pdf.
- Nasser, S.; Salama, I.; Mostafa, S. M.; Elgawish, M. S. Comparative High-Performance Liquid Chromatographic and High-Performance Thin-Layer Chromatographic Study for the Simultaneous Determination of Dapagliflozin and Metformin Hydrochloride in Bulk and Pharmaceutical Formulation. J. Planar Chromat. 2018, 31, 469–476. DOI: https://doi.org/10.1556/1006.2018.31.6.7.
- Kommineni, V.; Chowdary, K. P.; Prasad, S. V. Development and Validation of a New HPLC Method for the Simultaneous Estimation of Saxagliptine and Dapagliflozin and Its Application in Pharmacokinetic Studies. Int. Res. J. Pharm. Med. Sci. 2018, 1, 16–24. http://irjpms.com/wp-content/uploads/2018/10/IRJPMS-V1N6P71-18.pdf.
- Khalil, G. A.; Salama, I.; Gomaa, M. S.; Helal, M. A. Validate DRP-HPLC Method for Simultaneous Determination of Canagliflozin, Dapagliflozin, Empagliflozin and Metformin. Int. J. Pharm. Chem. Biol. Sci. 2018, 8, 01–13. https://web.a.ebscohost.com/abstract?direct=true&profile=ehost&scope=site&authtype=crawler&jrnl=22499504&AN=128417162&h=42MlRlcmRWBYVRxOffkuEafbh3aIs3UUWeAZqPGpf0wgmmUNp9TAdVOOkzq0Rhfjx%2btFTgDZUjddZuR5QdO26w%3d%3d&crl=c&resultNs=AdminWebAuth&resultLocal=ErrCrlNotAuth&crlhashurl=login.aspx%3fdirect%3dtrue%26profile%3dehost%26scope%3dsite%26authtype%3dcrawler%26jrnl%3d22499504%26AN%3d128417162.
- Agarwal, B.; Gandhi, S. Article Details Potential of RP-HPLC-DAD-MS for the Qualitative and Quantitative Analysis of Dapagliflozin in Tablets and Degradants. Indian Drugs 2018, 55, 45–49. http://www.indiandrugsonline.org/issuesarticle-details?id=ODY0.
- Manoharan, G.; Ismaiel, A. M.; Ahmed, Z. M. Stability-Indicating RP-HPLC Method Development for Simultaneous Determination and Estimation of Dapagliflozin in Raw and Tablet Formulation. Asian J. Civil. Stud. 2018, 4, 1–64. http://chemrj.org/download/vol-3-iss-2-2018/chemrj-2018-03-02-159-164.pdf. DOI: https://doi.org/10.9734/AJOCS/2018/40542.
- Game, M. D.; Bopudi, N. Development and Validation of Stability Indicating HPLC Method for Estimation of Dapagliflozin in Marketed Formulation. Int. J. Pharm. Pharm. Res. 2018, 12, 123–144.
- Urooj, A.; Sundar, P. S.; Vasanthi, R.; Raja, M. A.; Dutt, K. R.; Rao, K. N.; Ramana, H. Development and Validation of RP-HPLC Method for Simultaneous Estimation of Dapagliflozin and Metformin in Bulk and in Synthetic Mixture. World J. Pharm. Pharm, Sci. 2017, 6, 2139–2150. DOI: https://doi.org/10.20959/wjpps20177-9657.
- Sarkar, S.; Patel, V. P. Method Development & Validation of Dapagliflozin Drug in Bulk and Tablet Dosage Form by RP-HPLC. Int. J. Pharm. Res. Health Sci. 2017, 5, 1755–1759. https://doi.org/10.1515/chem-2016-0023.
- Sanagapati, M.; Dhanalakshmi, K.; Nagarjunareddy, G.; Sreenivasa, S. Development and Validation of a RP-HPLC Method for the Estimation of Dapagliflozin in API. Int. J. Pharm. Sci. Res. 2014, 5, 5394–5397.
- Sabbagh, B.; Lokesh, B.; Akouwah, G. A. Validated RP-HPLC and UV-Spectroscopy Methods for the Estimation of Dapagliflozin in Bulk and in Tablets. Indian Drugs 2017, 54, 44–51. http://www.indiandrugsonline.org/issuesarticle-details?id=NjQ5.
- Kommineni, V.; Chowdary, K. P.; Prasad, S. V. Development of a New Stability Indicating rp-Hplc Method for Simultaneous Estimation of Saxagliptine and Dapagliflozin and Its Validation as per ICH Guidelines. Indo. Am. J. Pharm. Sci. 2017, 4, 2920–2932. https://zenodo.org/record/892231#.XjLIfjIzaM8.
- Debata, J.; Kumar, S.; Jha, S. K.; Khan, A. A New RP-HPLC Method Development and Validation of Dapagliflozin in Bulk and Tablet Dosage Form. Int. J. Drug. Dev. Res. 2017, 9, 48–51. https://www.researchgate.net/profile/Sajal_Jha/publication/318900476_International_Journal_of_Drug_Development_and_Research/links/59842ec4a6fdccb3bfcb4403/International-Journal-of-Drug-Development-and-Research.pdf.
- Deepan, T.; Rao, M. B.; Dhanaraju, M. D. Development of Validated Stability Indicating Assay Method for SimultaneousEstimation of Metformin and Dapagliflozin by RP-HPLC. Eur. J. Appl. Sci. 2017, 9, 189–199. https://doi.org/10.5829/idosi.ejas.2017.189.199.
- Shakirbasha, S.; P, S. Development and Validation of Dapagliflozin by Reversed–Phase High Performance Liquid Chromatography Method and Forced Degradation Studies. Asian J. Pharm. Clin. Res. 2017, 10, 101–105. DOI: https://doi.org/10.22159/ajpcr.2017.v10i11.19705.
- Shyamala, M.; Nidhi, B.; Kavitha, M.; Pooja Sharma, J. V. Validated RP-HPLC Method for Simultaneous Estimation of Metformin Hydrochloride and Dapagliflozin in Tablet Dosage Form. Asian J. Biochem. Pharm. Res. 2015, 2, 109–113.
- Sanagapati, M.; Lakshmi, D. K.; Reddy, N. G.; Sreenivasa, S. Development and Validation of stability-Indicating RP-HPLC Method for Determination of Dapagliflozin. J. Adv. Pharm. Educ. Res. 2014, 4, 350–353. https://www.speronline.com/japer/Articlefile/250.pdf.
- Jayaraman, K.; Alexander, A. J.; Hu, Y.; Tomasella, F. P. A Stepwise Strategy Employing Automated Screening and DryLab Modeling for the Development of Robust Methods for Challenging High Performance Liquid Chromatography Separations: A Case Study. Anal. Chim. Acta. 2011, 696, 116–124. DOI: https://doi.org/10.1016/j.aca.2011.04.010.
- Kalgutkar, A. S.; Tugnait, M.; Zhu, T.; Kimoto, E.; Miao, Z.; Mascitti, V.; Yang, X.; Tan, B.; Walsky, R. L.; Chupka, J.; et al. Preclinical Species and Human Disposition of PF-04971729, a Selective Inhibitor of the Sodium-Dependent Glucose Cotransporter 2 and Clinical Candidate for the Treatment of Type 2 Diabetes Mellitus. Drug Metab. Dispos. 2011, 39, 1609–1619. DOI: https://doi.org/10.1124/dmd.111.040675.
- El-Shoubashy, O. H.; Beltagy, Y. A.; Issa, A. E.; El-Kafrawy, D. S. Comparative Study of HPLC-DAD and HPTLC for the Simultaneous Determination of a New Multitarget Antidiabetic Ternary Mixture in Combined Tablets. J. Planar Chromat. 2020, 33, 59–52. DOI: https://doi.org/10.1007/s00764-019-00003-1.
- Dighe, N. S. Simultaneous Estimation, Validation and Force Degradation Study of Saxagliptin and Dapagliflozin by RP-HPLC Method. Purakala with ISSN 0971-2143 is an UGC CARE J. 2020, 31, 1019–1035. https://www.purakala.com/index.php/0971-2143/article/view/97.
- Madhavi, S.; Rani, A. P. Development and Validation of a Method for Simultaneous Determination of Dapagliflozin and Saxagliptin in a Formulation by RP-UPLC. J. Pharm. Res. 2017, 16, 904–916.
- Kim, N. S.; Kim, K. Y.; Yoo, G. J.; Lee, J. H.; Park, H. N.; Park, S. K.; Baek, S. Y. Determination of 26 anti-Diabetic Compounds in Dietary Supplements Using a Validated UPLC Method. Food Addit. Contam. Part A Chem. Anal. Control. Expo. Risk Assess. 2018, 35, 387–394. DOI: https://doi.org/10.1080/19440049.2017.1332429.
- Ahmed, H. M.; Omar, M. A.; Batakoushy, H. A.; Hamid, M. A. HPTLC-Densitometric Analysis of Selected Antidiabetic Drugs in Presence of Their Degradation Products. Microchem. J. 2020, 154, 104560. DOI: https://doi.org/10.1016/j.microc.2019.104560.
- Suma, B.; Deveswaran, R.; Premnath, S. A New High-Performance Thin Layer Chromatographic Method Development and Validation of Dapagliflozin in Bulk and Tablet Dosage Form. Int. J. Pharm. Pharm. Sci. 2019, 11, 58–63. https://innovareacademics.org/journals/index.php/ijpps/article/download/34339/20517. DOI: https://doi.org/10.22159/ijpps.2019v11i8.34339.
- Zameeruddin, M.; Bundel, S. S.; Bharkad, V. B.; Khan, H. N.; Thoke, S. T. Development and Validation of UV Spectroscopic Method for Simultaneous Estimation of Dapagliflozin and Sexagliptin in Synthetic Mixture. Int. J. Pharm. Anal. Res. 2019, 8, 59–66. http://www.ijpar.com/sites/default/files/articles/IJPAR_19_105_59-66.pdf.
- Bodade, B. J.; Kanade, D. A.; Chaudhari, S. S. Quantitative Estimation of Dapagliflozin in Blood Plasma by Using UV Spectroscopy. Pharm. Anal. Acta 2019, 10, 1–3. https://pdfs.semanticscholar.org/286b/ce237969af477733ee1c77b4461c56656074.pdf.
- Lotfy, H. M.; Mohamed, D.; Elshahed, M. S. Novel Univariate Spectrophotometric Determination of the Recently Released Solid Dosage Form Comprising Dapagliflozin and Saxagliptin via Factorized Response Spectra: Assessment of the Average Content and Dosage Unit Uniformity of Tablets. Spectrochim. Acta Part A 2019, 222, 117120. DOI: https://doi.org/10.1016/j.saa.2019.05.025.
- Suthar, A. M.; Prajapati, L. M.; Joshi, A. K.; Patel, J. R.; Kharodiya, M. L.; Prajapati, L. M. Estimation of Saxagliptin Hydrochloride and Dapagliflozin Propendiol Monohydrate in Combined Dosage Form. J. Innov. Appl. Pharm. Sci. 2018, 3, 01–07. http://www.jiapsonline.com/VolumeArticles/FullTextPDF/41_JIAPSV3I201.pdf.
- de Meira, R. Z. C.; Maciel, A. B.; Murakami, F. S.; de Oliveira, P. R.; Bernardi, L. S. In Vitro Dissolution Profile of Dapagliflozin: Development, Method Validation, and Analysis of Commercial Tablets. Int. J. Anal. Chem. 2017, 2017, 2951529–2951506. DOI: https://doi.org/10.1155/2017/2951529.
- Mante, G. V.; Gupta, K. R.; Hemke, A. T. Estimation of Dapagliflozin from Its Tablet Formulation by UV-Spectrophotometry. Pharm. Methods 2017, 8, 102–107. http://www.phmethods.net/sites/default/files/10.5530phm.2017.8.16.pdf. DOI: https://doi.org/10.5530/phm.2017.8.16.
- Jani, B. R.; Shah, K. V.; Kapupara, P. P. Development and Validation of UV Spectroscopic First Derivative Method for Simultaneous Estimation of Dapagliflozin and Metformin Hydrochloride in Synthetic Mixture. J. Bioequiv. 2015, 1, 102. https://www.researchgate.net/profile/Dr_Pankaj_Kapupara/publication/279183857_DEVELOPMENT_AND_VALIDATION_OF_UV_SPECTROSCOPIC_METHOD_FOR_SIMULTANEOUS_ESTIMATION_OF_DAPAGLIFLOZIN_AND_METFORMIN_HYDROCHLORIDE_IN_SYNTHETIC_MIXTURE/links/5720551608aed056fa23670c.pdf.
- Bhavyasri, K.; Surekha, T. Bioanalytical Method Development and Validation of Dapagliflozin and Metormin Hydrochloride in Combined Dosage Form Using UV-Spectroscopy. GOR. 2020, 33, 272–283. http://www.lemma-tijdschriften.nl/gallery/goj-1509.pdf. DOI: https://doi.org/10.37896/GOR33.02/043.
- Surendran, S.; Paul, D.; Pokharkar, S.; Deshpande, A.; Giri, S.; Satheeshkumar, N. A LC-MS/MS Method for Simultaneous Estimation of a Novel anti-Diabetic Combination of Saxagliptin and Dapagliflozin Using a Polarity Switch Approach: Application to in Vivo Rat Pharmacokinetic Study. Anal. Methods 2019, 11, 219–226. DOI: https://doi.org/10.1039/C8AY02087F.
- Shah, P. A.; Shrivastav, P. S.; Shah, J. V.; George, A. Simultaneous Quantitation of Metformin and Dapagliflozin in Human Plasma by LC–MS/MS: Application to a Pharmacokinetic Study. Biomed. Chromatogr 2019, 33, 4453. https://doi.org/10.1002/bmc.4453.
- Aubry, A. F.; Gu, H.; Magnier, R.; Morgan, L.; Xu, X.; Tirmenstein, M.; Wang, B.; Deng, Y.; Cai, J.; Couerbe, P.; Arnold, M. Validated LC-MS/MS Methods for the Determination of Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor in Normal and ZDF Rat Plasma. Bioanalysis 2010, 2, 2001–2009. DOI: https://doi.org/10.4155/bio.10.139.
- El-Zaher, A. A.; Hashem, H. A.; Elkady, E. F.; Allam, M. A. A Validated LC-MS/MS Bioanalytical Method for the Simultaneous Determination of Dapagliflozin or Saxagliptin with Metformin in Human Plasma. Microchem. J. 2019, 149, 104017. DOI: https://doi.org/10.1016/j.microc.2019.104017.
- Phanindra, A.; Kumar, Y. S. Development and Validation of Sensitive LC-ESI-MS/MS Method for the Simultaneous Estimation of Dapagliflozin and Saxagliptin in Human Plasma. Int. J. Pharm. Pharm. Sci. 2019, 11, 55–59. https://pdfs.semanticscholar.org/adfa/3fe2141feb97facd3c7d86a2da181b1bb1e9.pdf. DOI: https://doi.org/10.22159/ijpps.2019v11i4.31249.
- Maher, H. M.; Abdelrahman, A. E.; Alzoman, N. Z.; Aljohar, H. I. Stability-Indicating Capillary Electrophoresis Method for the Simultaneous Determination of Metformin Hydrochloride, Saxagliptin Hydrochloride, and Dapagliflozin in Pharmaceutical Tablets. J. Liq. Chromatogr. Relat. Technol. 2019, 42, 161–171. DOI: https://doi.org/10.1080/10826076.2019.1590208.
- Kumar, C. V.; Aparna, P.; Kumar, Y. R.; Reddy, G. R. Determination of Residual Solvents in Dapagliflozin Amorphous by Gas Chromatography with Static Head Space Method. Pharm. Lett. 2016, 8, 349–356. https://pdfs.semanticscholar.org/6da0/06be31b2aa1a4f7e91cbf3c9aadd853e7192.pdf.
- Kazi, M.; Alqahtani, A. A.; Alsaadi, B. S.; Alkholief, M.; Alanazi, F. K. UHPLC Method Development for Determining Sitagliptin and Dapagliflozin in Lipid-Based Self-Nanoemulsifying Systems as Combined Dose in Commercial Products and Its Application to Pharmacokinetic Study of Dapagliflozin in Rats. Pharm. Chem. J. 2019, 53, 79–87. DOI: https://doi.org/10.1007/s11094-019-01959-4.
- http://tlcstandards.com/ProdDetail.aspx?ID=D-624&name=DAPAGLIFLOZIN (accessed Jan 21, 2020).